The politicization of the FDA under the Trump administration has led to concerns about its ability to maintain scientific standards, rigorous review, transparency, and public trust. Inconsistent decision-making in high-profile drug reviews, such as Moderna's mRNA influenza vaccine, raises questions about political appointees exerting influence over scientific and regulatory decisions. The National Priority Review Voucher Program, aimed at reducing review timelines for products addressing urgent ...